The short version
- New studies suggest semaglutide and tirzepatide can diminish cravings for alcohol by altering neural reward responses.
- Patients report diverse outcomes, ranging from reduced intake and nausea to unchanged drinking habits or social difficulties.
- Medical guidelines currently lack specific directives on alcohol consumption while using these weight-loss treatments.
A growing number of individuals taking popular weight-loss medications are reporting significant changes in their relationship with alcohol. Drugs such as Wegovy, Mounjaro, and Ozempic, which contain active ingredients like semaglutide or tirzepatide, are designed to mimic the hormone GLP-1. This mechanism suppresses appetite and promotes satiety, aiding in weight reduction. However, users are increasingly noting that these substances also impact their desire for and tolerance of alcohol, a side effect that has drawn attention from both patients and researchers.
Early scientific inquiry indicates that these medications may influence the brain’s reward system. Dr. Christian Hendershot of the University of South Carolina notes that because the drugs affect how the brain processes rewards, they can lower cravings for various substances, including nicotine and alcohol. A small-scale study published in 2025 by Hendershot found that participants with alcohol use disorder experienced reduced cravings while taking Ozempic. Alcohol use disorder is clinically defined as drinking patterns that cause harm or distress.
Further evidence comes from a recent study by the University of Colorado Anschutz, which examined GLP-1 medications in pill form. The research suggested that individuals with mild to moderate alcohol use disorder experienced fewer days of heavy drinking while on the medication. These findings align with anecdotal reports from users who describe a diminished interest in alcohol or an inability to consume large quantities without adverse physical reactions.
Personal accounts highlight the variability of these effects. Lisa Rees, a 46-year-old from South Wales, began taking Wegovy in April primarily for weight loss. She had previously consumed between six and eight bottles of wine weekly, often worrying about the health implications. After starting the medication, she found that after just a couple of glasses, she physically could not drink more. Her weekly consumption dropped by more than half, allowing her to remain socially engaged without the excessive intake she once practiced.
Warren Thomas, 45, from Colchester, experienced a similar shift shortly after beginning Mounjaro in mid-June. Friends on the medication had warned him of potential changes in alcohol tolerance. Within 24 hours of his first dose, he reported losing his appetite for beer entirely. During a recent social event, he felt lightheaded and giddy after only two beers, describing his current tolerance level as effectively zero. For both Rees and Thomas, the reduction in drinking has been viewed as a beneficial secondary outcome.
Not all users view these changes positively. Faye Goodwin, a 20-year-old recent graduate who has taken Mounjaro since age 18, reports that alcohol quickly induces nausea and acid reflux. She notes that when she paused her injections for a month, she was able to drink without these symptoms returning. For young adults like Goodwin, where alcohol often plays a central role in social bonding, the inability to drink comfortably can feel isolating or disruptive to their social lives.
Medical professionals are still navigating how to advise patients on this issue. Professor Russell Hearn, a GP and professor of medicine at King’s College London, points out that the British National Formulary, a key guide for healthcare providers, does not currently offer formal advice on whether patients should abstain from alcohol while on these drugs. Hearn typically counsels patients to consider the high caloric content of alcohol, noting that reducing intake supports weight-loss goals alongside dietary changes.
The broader implications of these findings remain under investigation. While some users experience a welcome decrease in consumption, others face physical discomfort or social challenges. The NHS recommends limiting alcohol to 14 units per week to prevent long-term health risks such as liver damage and high blood pressure. As more data emerges on how GLP-1 agonists interact with substance use, healthcare providers may need to develop clearer guidelines to help patients manage these unexpected side effects.
Current reporting suggests that while the mechanism behind reduced cravings is becoming clearer through studies on brain reward pathways, individual responses are highly inconsistent. Some users notice no change in their drinking habits at all. Until more comprehensive clinical data is available, patients are encouraged to monitor their own reactions and consult with healthcare providers about any significant changes in substance use or tolerance.
The intersection of weight management and substance use presents a complex landscape for modern medicine. As these drugs become more widely prescribed, understanding their full spectrum of effects—including those on alcohol consumption—will be crucial. For now, the experience remains mixed, offering health benefits for some while posing social and physical adjustments for others.
Sources behind this briefing
Go to the original reporting
- BBC News↗How weight-loss medication is changing relationships with alcohol
